Role of Biomarkers in Immune checkpoint inhibitor Antibody Development

Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:

 

• Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
• Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
• Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
• Biomarkers sourced During clinical Trials
• Biomarkers Insight By Immune Checkpoint Inhibitors Classification
• Insight On  Biomarkers Sourced From Trials By Drugs & Indication
• Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
• Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication

 

Download Report:

 

https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers

 

A checkpoint inhibitor is a drug used in immunotherapy that blocks the proteins present in tumor cells that inhibit the immune system. Several immune checkpoint inhibitors have entered the market which block different proteins such as CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death-ligand 1). To date, sixteen immune checkpoint inhibitors including Keytruda, Bavencio, Opdivo, Yervoy, Jemperli Tecentriq, Imfinzi, and Libtayo has entered the globalmarket which has shown high adoption rates among cancer patients.  

 

The promising response of the approved immune checkpoint inhibitors in the market has propelled the further research and development in this sector. Apart from CTLA-4 and PD-L1/PD-1, researchers have identified several other immune checkpoint targets including lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and ITM domain (TIGIT), T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3), V-domain Ig suppressor of T-cell activation (VISTA), and others. These are mainly present in initial stages of clinical development and are expected to enter the market during the forthcoming years.

 

The global immune checkpoint inhibitor market is driven by the number of research developments undertaken by industry contributions as well as academic constitutions. The global market is experiencing several collaborations wherein companies are combining their core competencies to fasten their research their research program. For instance, Akso Biopharmaceutical and Huadong Medicine entered into an exclusive collaboration to develop and commercialize AB002, a bi-functional fusion protein inhibiting immune checkpoint and activating natural killer (NK) cells for the treatment of solid tumors, in the Asia Pacific Ex-Japan region. AKSO will retain all rights to AB002 in the rest of the world. The other key players in the global immune checkpoint market include Bristol Myer Squibb, Merck, Roche, AstraZeneca, Novartis, and Ono Pharmaceutical.

 

Apart from monotherapy, several ongoing clinical trials are also evaluating the role of drugs in combinational therapy to enhance the further efficacy and overcome drug resistance. Recently in 2022, Hepion Pharmaceutical announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse survival when combined with an anti-PD1 antibody. Furthermore, Zenith Epigenetics also dosed the first patient with a combination of ZEN-3694 (BET inhibitor) + Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in solid tumor. The part-IB of the trial will also evaluate triple combination of ZEN3694, Opdivo, and Yervoy in ovarian cancer patients. The large number of ongoing clinical trials and robust clinical pipeline suggests that immune checkpoint inhibitors will held a substantial share in the global cancer therapeutics market in coming years.

 

The immune checkpoint inhibitor market is forecast to grow substantially during the forecast period due to an increase in demand for cancer therapeutics, favorable reimbursement policies offered by manufacturers and insurance companies in some countries, and an increase in the prevalence of cancer across the globe. Further, surge in awareness regarding the availability of checkpoint inhibitors for cancer management, the increase in research and development activities, and the increase in adoption of immune checkpoint inhibitor drugs are the key factors driving the growth of market. As per our report findings, the global immune checkpoint inhibitor market is expected to surpass US$ 28 Billion by 2028.

 

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies.

 

Contact:

 

Neeraj Chawla

Kuick research

Research Head

+91-981410366

neeraj@kuickresearch.com

https://www.kuickresearch.com